Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
NCT00396864
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
51
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Lymphomas
Interventions
DRUG:
NPI-0052
Sponsor
Celgene